Increased Osteopontin Expression in Dendritic Cells Amplifies IL-17 Production by CD4+ T Cells in Experimental Autoimmune Encephalomyelitis and in Multiple Sclerosis
Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cel...
Saved in:
| Published in | The Journal of immunology (1950) Vol. 181; no. 11; pp. 7480 - 7488 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Am Assoc Immnol
01.12.2008
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation toward IFN-γ-producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS are unknown. We found that during EAE, Opn expression is elevated in DCs both in the periphery and in the CNS. There was increased expression of Opn receptor on T cells, and Opn induced IL-17 production by CD4+ T cells via the β3 integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS, we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, β3, and αv on T cells. Furthermore, Opn-stimulated CD4+ T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC-produced Opn both in EAE and MS that is linked to the production of IL-17. |
|---|---|
| AbstractList | Osteopontin (Opn) is a broadly expressed pleiotropic cytokine and has been shown to play an important role in various autoimmune diseases including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation towards IFN-γ producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS is unknown. We found that during EAE Opn expression is elevated in DCs both in the periphery and in the central nervous system. There was increased expression of Opn receptor on T cells and Opn induced IL-17 production by CD4
+
T cells via the β3 integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, β3 and αv on T cells. Furthermore, Opn stimulated CD4
+
T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC produced Opn both in EAE and MS that is linked to the production of IL-17. Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation toward IFN-γ-producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS are unknown. We found that during EAE, Opn expression is elevated in DCs both in the periphery and in the CNS. There was increased expression of Opn receptor on T cells, and Opn induced IL-17 production by CD4+ T cells via the β3 integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS, we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, β3, and αv on T cells. Furthermore, Opn-stimulated CD4+ T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC-produced Opn both in EAE and MS that is linked to the production of IL-17. Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation toward IFN-gamma-producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS are unknown. We found that during EAE, Opn expression is elevated in DCs both in the periphery and in the CNS. There was increased expression of Opn receptor on T cells, and Opn induced IL-17 production by CD4(+) T cells via the beta(3) integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS, we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, beta(3), and alpha(v) on T cells. Furthermore, Opn-stimulated CD4(+) T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC-produced Opn both in EAE and MS that is linked to the production of IL-17. Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation toward IFN-gamma-producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS are unknown. We found that during EAE, Opn expression is elevated in DCs both in the periphery and in the CNS. There was increased expression of Opn receptor on T cells, and Opn induced IL-17 production by CD4(+) T cells via the beta(3) integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS, we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, beta(3), and alpha(v) on T cells. Furthermore, Opn-stimulated CD4(+) T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC-produced Opn both in EAE and MS that is linked to the production of IL-17.Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). It is reported that Opn exacerbates EAE by skewing T cell differentiation toward IFN-gamma-producing Th1 cells. Opn expression in dendritic cells (DCs) and its role in IL-17 induction from T cells during EAE or MS are unknown. We found that during EAE, Opn expression is elevated in DCs both in the periphery and in the CNS. There was increased expression of Opn receptor on T cells, and Opn induced IL-17 production by CD4(+) T cells via the beta(3) integrin receptor and Opn inhibited IL-10 production via the CD44 receptor. Furthermore, anti-Opn treatment reduced clinical severity of EAE by reducing IL-17 production. Anti-Opn was also effective in reducing clinical severity of EAE when given after the appearance of clinical symptoms. Analogous to EAE, in subjects with MS, we found increased expression of Opn in DCs and increased expression of the Opn receptors CD44, beta(3), and alpha(v) on T cells. Furthermore, Opn-stimulated CD4(+) T cells from MS patients produced significantly higher amounts of IL-17. Our results demonstrate a role for DC-produced Opn both in EAE and MS that is linked to the production of IL-17. |
| Author | Mittal, Akanksha Murugaiyan, Gopal Weiner, Howard L |
| Author_xml | – sequence: 1 fullname: Murugaiyan, Gopal – sequence: 2 fullname: Mittal, Akanksha – sequence: 3 fullname: Weiner, Howard L |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19017937$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9Ut1u0zAYtdAQ6wZvgJCvENKUYjuJk3CBVHUFKhUNiXFtOc6X1ZNjZ3ZC6QPtPXFoNw0uuLIsnz8dnzN0Yp0FhF5TMs9IVr2_1V03WmfmtKRzSudFVpJnaEbznCScE36CZoQwltCCF6foLIRbQggnLHuBTmlFaFGlxQzdr63yIAM0-CoM4HpnB23x6lfvIQTtLI63S7CN14NWeAnGBLzoeqNbDQGvN1Eff_OuGdUwoes9Xl5mF_j6CD1ogdcd2EEavBgH9yc44JVV0G-lcd0eTFQPWNpmInwdzaB7A_i7MuBd0OElet5KE-DV8TxHPz6trpdfks3V5_VysUlUVrAhaRltAXLakDxreCbbpm5UWyvVlGXNeCVLwooya6VKW1lCQRlNY5esrinhacXSc_TxoNuPdQeNipm9NKKP8aXfCye1-PvF6q24cT8F43lK8jIKvD0KeHc3QhhEp4OKTUgLbgyCVyUp84pH4JunTo8WDz8TAR8OABUbCB5aofQgp46jsTaCEjHNQDzMQMQZCErFNINIzv4hP-r_n_buQNvqm-1OexChk8bEiFTsdrun0N_R8MvV |
| CitedBy_id | crossref_primary_10_1016_j_jneuroim_2012_10_003 crossref_primary_10_3390_molecules26175227 crossref_primary_10_1172_JCI88606 crossref_primary_10_1186_s13054_015_0782_3 crossref_primary_10_1093_intimm_dxp021 crossref_primary_10_1073_pnas_2322009121 crossref_primary_10_1371_journal_pone_0309563 crossref_primary_10_4049_jimmunol_1701345 crossref_primary_10_1155_2016_7675437 crossref_primary_10_1177_1352458510382247 crossref_primary_10_1212_NXI_0000000000200265 crossref_primary_10_1186_s12974_025_03376_9 crossref_primary_10_1038_cmi_2017_94 crossref_primary_10_1586_eci_10_82 crossref_primary_10_1016_j_cyto_2022_156107 crossref_primary_10_1097_ACI_0b013e32834ecc9a crossref_primary_10_2174_1381612826666200406081920 crossref_primary_10_1371_journal_pone_0029309 crossref_primary_10_1016_j_bbi_2011_04_006 crossref_primary_10_3389_fimmu_2017_00321 crossref_primary_10_1016_j_coi_2010_08_017 crossref_primary_10_4049_jimmunol_0901017 crossref_primary_10_1177_1352458509359723 crossref_primary_10_1016_j_jneuroim_2012_10_013 crossref_primary_10_1007_s10787_022_00932_0 crossref_primary_10_1111_cen3_12130 crossref_primary_10_1007_s12079_009_0068_0 crossref_primary_10_1038_nri2548 crossref_primary_10_1111_j_1365_2249_2010_04148_x crossref_primary_10_1007_s11064_020_03119_7 crossref_primary_10_1038_icb_2012_14 crossref_primary_10_1007_s12079_020_00554_7 crossref_primary_10_1111_jcmm_15641 crossref_primary_10_1371_journal_pone_0064277 crossref_primary_10_1016_j_jaut_2024_103298 crossref_primary_10_1212_WNL_0b013e3181c97c8f crossref_primary_10_1016_j_cyto_2018_03_013 crossref_primary_10_1016_j_cytogfr_2019_05_004 crossref_primary_10_1007_s00011_018_1200_5 crossref_primary_10_1016_j_arr_2021_101333 crossref_primary_10_1016_j_jhep_2022_06_025 crossref_primary_10_1016_j_jaut_2011_09_002 crossref_primary_10_1002_term_2866 crossref_primary_10_1007_s00403_020_02168_w crossref_primary_10_1038_cmi_2012_10 crossref_primary_10_1002_art_30108 crossref_primary_10_3390_cancers15133480 crossref_primary_10_1074_jbc_M114_572172 crossref_primary_10_1016_j_autrev_2015_07_014 crossref_primary_10_1073_pnas_1316447111 crossref_primary_10_1371_journal_ppat_1009618 crossref_primary_10_1002_art_24625 crossref_primary_10_1111_j_1600_065X_2012_01126_x crossref_primary_10_1016_j_bbacli_2015_01_003 crossref_primary_10_1111_cen_12229 crossref_primary_10_1007_s12026_010_8179_5 crossref_primary_10_3109_08916930903540424 crossref_primary_10_3390_jcm12062433 crossref_primary_10_3390_nu9080817 crossref_primary_10_1038_cmi_2012_67 crossref_primary_10_1089_jir_2010_0082 crossref_primary_10_1038_s41581_023_00760_7 crossref_primary_10_1016_j_bbi_2013_08_009 crossref_primary_10_1016_j_jneuroim_2009_10_015 crossref_primary_10_1007_s12020_015_0552_7 crossref_primary_10_1111_j_1600_0625_2009_00926_x crossref_primary_10_1212_WNL_0b013e3182518302 crossref_primary_10_3389_fnut_2022_1054431 crossref_primary_10_1002_eji_201040796 crossref_primary_10_1016_j_celrep_2016_06_065 crossref_primary_10_1016_j_jneuroim_2015_05_022 crossref_primary_10_1126_scitranslmed_3003041 crossref_primary_10_1186_1742_2094_9_158 crossref_primary_10_1016_j_tips_2010_03_004 crossref_primary_10_1016_j_bbadis_2017_10_006 crossref_primary_10_1038_s41467_018_03186_z crossref_primary_10_1073_pnas_1002099107 crossref_primary_10_1016_j_jneuroim_2013_12_013 crossref_primary_10_1155_2013_518094 crossref_primary_10_1016_j_acthis_2012_08_004 crossref_primary_10_1371_journal_pone_0215883 crossref_primary_10_1177_1352458509103318 crossref_primary_10_1371_journal_pone_0190252 crossref_primary_10_1016_j_gene_2018_10_038 crossref_primary_10_1038_s41598_018_34734_8 crossref_primary_10_1155_2012_212893 crossref_primary_10_1038_ng_749 crossref_primary_10_1177_0963689718756070 crossref_primary_10_1007_s10555_010_9221_8 crossref_primary_10_1080_00207454_2019_1694925 crossref_primary_10_1007_s12028_014_0094_5 crossref_primary_10_1155_2018_3458439 crossref_primary_10_1002_acn3_52087 crossref_primary_10_1111_pai_12926 crossref_primary_10_4049_jimmunol_1901168 crossref_primary_10_2174_0929867327666200515101228 crossref_primary_10_3390_cancers14153649 crossref_primary_10_1007_s00005_014_0294_x crossref_primary_10_18632_aging_101773 crossref_primary_10_1371_journal_pone_0039576 crossref_primary_10_1111_exd_12649 crossref_primary_10_14336_AD_2019_0618 crossref_primary_10_1002_1873_3468_14262 crossref_primary_10_1002_eji_201646792 crossref_primary_10_1016_j_pbiomolbio_2017_12_004 crossref_primary_10_1007_s00005_017_0455_9 crossref_primary_10_1100_2011_873895 crossref_primary_10_1016_j_aquaculture_2020_734969 crossref_primary_10_1155_2016_9345495 crossref_primary_10_1016_j_jns_2013_04_024 crossref_primary_10_1016_j_humimm_2011_03_016 crossref_primary_10_1186_s12879_024_10076_x crossref_primary_10_1152_ajpcell_00376_2021 crossref_primary_10_1096_fj_13_228809 crossref_primary_10_3390_nu16020312 crossref_primary_10_1038_ni_1803 crossref_primary_10_1146_annurev_immunol_032713_120227 crossref_primary_10_1136_annrheumdis_2021_220280 crossref_primary_10_3109_08923973_2014_897726 crossref_primary_10_1016_j_cyto_2012_10_027 crossref_primary_10_2353_ajpath_2010_090488 crossref_primary_10_1189_jlb_0412194 crossref_primary_10_1177_1352458512473189 crossref_primary_10_1016_j_jneuroim_2013_07_005 crossref_primary_10_1111_tbed_13559 crossref_primary_10_3390_jcm13030655 crossref_primary_10_4049_jimmunol_1101524 crossref_primary_10_1038_s41598_018_26187_w crossref_primary_10_1097_SHK_0000000000000611 crossref_primary_10_1073_pnas_2116256118 crossref_primary_10_1111_j_1759_1961_2011_00019_x crossref_primary_10_1002_eji_200939814 crossref_primary_10_1186_s12974_015_0348_y crossref_primary_10_1016_j_msard_2016_02_013 crossref_primary_10_1016_j_gene_2019_02_100 crossref_primary_10_1111_j_1600_065X_2012_01135_x crossref_primary_10_1182_blood_2010_04_281659 crossref_primary_10_3892_br_2016_589 crossref_primary_10_1002_art_30127 crossref_primary_10_1155_2013_859145 crossref_primary_10_1371_journal_pone_0011520 crossref_primary_10_1177_0022034515605270 crossref_primary_10_1016_j_neuroscience_2017_03_020 crossref_primary_10_1016_j_bbi_2013_11_021 crossref_primary_10_3168_jds_2013_7059 crossref_primary_10_3390_ijms22168946 |
| Cites_doi | 10.1038/ni.1610 10.1093/rheumatology/keh558 10.1126/science.287.5454.860 10.1016/j.cell.2006.07.035 10.1016/S0002-9440(10)65584-8 10.1172/JCI12980 10.1038/ni1261 10.1292/jvms.68.379 10.1016/j.jneuroim.2004.09.004 10.1016/j.jaut.2004.03.007 10.1038/ni0407-345 10.1038/ni0107-19 10.1146/annurev.immunol.23.021704.115707 10.1126/science.1062960 10.4049/jimmunol.168.5.2096 10.1073/pnas.0508666102 10.4049/jimmunol.156.1.5 10.1196/annals.1394.023 10.2741/2390 10.4049/jimmunol.177.1.566 10.4049/jimmunol.176.12.7768 10.1016/j.jneuroim.2004.06.007 10.1172/JCI25308 10.1016/j.immuni.2006.06.002 10.1086/444430 10.1182/blood-2004-08-3228 10.1038/ni1415 10.1172/JCI200319190 10.1038/nature01355 10.1136/gut.2004.048298 10.1038/nm1715 10.1038/ni1496 10.1016/S1074-7613(03)00113-4 |
| ContentType | Journal Article |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.4049/jimmunol.181.11.7480 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1550-6606 |
| EndPage | 7488 |
| ExternalDocumentID | PMC2653058 19017937 10_4049_jimmunol_181_11_7480 www181_11_7480 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: F32AI075761 – fundername: NINDS NIH HHS grantid: NS23132 – fundername: NINDS NIH HHS grantid: NS038037 – fundername: NIAID NIH HHS grantid: F32 AI075761 – fundername: NIAID NIH HHS grantid: AI043458 – fundername: NIAID NIH HHS grantid: R01 AI043458 – fundername: NINDS NIH HHS grantid: R01 NS023132 – fundername: NINDS NIH HHS grantid: P01 NS038037 |
| GroupedDBID | - 08R 2WC 34G 39C 3O- 53G 55 5GY 5RE 5VS 79B 85S 8RP AALRV AARDX ABEFU ABFLS ABOCM ABPPZ ABPTK ACGFS ACIWK ACNCT ACPRK ADACO ADBBV ADKFC AENEX AETEA AFFNX AFRAH AJYGW ALMA_UNASSIGNED_HOLDINGS BAWUL D0L DIK DU5 E3Z EBS EJD F5P FH7 FRP GX1 H13 IH2 K-O K78 KQ8 L7B MVM NEJ O0- OK1 P0W P2P PQEST PQQKQ R.V RHF RHI RZQ SJN TWZ WH7 WOQ X X7M XJT ZA5 ZE2 ZGI --- -~X .55 0R~ 18M 5WD AAYXX ABCQX ABDFA ABEJV ABGNP ABJNI ABXVV ACGFO ADIPN ADNWM ADXHL AFHIN AFOSN AGORE AHMMS AHWXS AIZAD ARBBW BCRHZ BTFSW CITATION OCZFY OWPYF ROX TR2 W8F XSW XTH YHG CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c472t-f21fee51d054d64afdbdcfbccd88b269a802784fac3fa8e712134042bb1063923 |
| ISSN | 0022-1767 1550-6606 |
| IngestDate | Thu Aug 21 18:37:37 EDT 2025 Fri Jul 11 09:32:09 EDT 2025 Fri May 30 10:59:44 EDT 2025 Tue Jul 01 03:26:00 EDT 2025 Thu Apr 24 22:58:36 EDT 2025 Tue Nov 10 19:22:50 EST 2020 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Language | English |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c472t-f21fee51d054d64afdbdcfbccd88b269a802784fac3fa8e712134042bb1063923 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 these authors contributed equally to this work |
| OpenAccessLink | https://journals.aai.org/jimmunol/article-pdf/181/11/7480/1259725/zim02308007480.pdf |
| PMID | 19017937 |
| PQID | 69808596 |
| PQPubID | 23479 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2653058 proquest_miscellaneous_69808596 pubmed_primary_19017937 crossref_citationtrail_10_4049_jimmunol_181_11_7480 crossref_primary_10_4049_jimmunol_181_11_7480 highwire_smallpub1_www181_11_7480 |
| ProviderPackageCode | RHF RHI CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2008-12-01 |
| PublicationDateYYYYMMDD | 2008-12-01 |
| PublicationDate_xml | – month: 12 year: 2008 text: 2008-12-01 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Journal of immunology (1950) |
| PublicationTitleAlternate | J Immunol |
| PublicationYear | 2008 |
| Publisher | Am Assoc Immnol |
| Publisher_xml | – name: Am Assoc Immnol |
| References | 2022123119205825700_R4 2022123119205825700_R3 2022123119205825700_R2 2022123119205825700_R1 2022123119205825700_R8 2022123119205825700_R7 2022123119205825700_R6 2022123119205825700_R31 2022123119205825700_R5 2022123119205825700_R30 2022123119205825700_R9 2022123119205825700_R29 2022123119205825700_R22 2022123119205825700_R21 2022123119205825700_R24 2022123119205825700_R23 2022123119205825700_R26 2022123119205825700_R25 2022123119205825700_R28 2022123119205825700_R27 2022123119205825700_R20 2022123119205825700_R19 2022123119205825700_R18 2022123119205825700_R11 2022123119205825700_R33 2022123119205825700_R10 2022123119205825700_R32 2022123119205825700_R13 2022123119205825700_R12 2022123119205825700_R15 2022123119205825700_R14 2022123119205825700_R17 2022123119205825700_R16 |
| References_xml | – ident: 2022123119205825700_R25 doi: 10.1038/ni.1610 – ident: 2022123119205825700_R5 doi: 10.1093/rheumatology/keh558 – ident: 2022123119205825700_R13 doi: 10.1126/science.287.5454.860 – ident: 2022123119205825700_R23 doi: 10.1016/j.cell.2006.07.035 – ident: 2022123119205825700_R33 doi: 10.1016/S0002-9440(10)65584-8 – ident: 2022123119205825700_R1 doi: 10.1172/JCI12980 – ident: 2022123119205825700_R19 doi: 10.1038/ni1261 – ident: 2022123119205825700_R8 doi: 10.1292/jvms.68.379 – ident: 2022123119205825700_R4 doi: 10.1016/j.jneuroim.2004.09.004 – ident: 2022123119205825700_R7 doi: 10.1016/j.jaut.2004.03.007 – ident: 2022123119205825700_R16 doi: 10.1038/ni0407-345 – ident: 2022123119205825700_R12 doi: 10.1038/ni0107-19 – ident: 2022123119205825700_R14 doi: 10.1146/annurev.immunol.23.021704.115707 – ident: 2022123119205825700_R3 doi: 10.1126/science.1062960 – ident: 2022123119205825700_R9 doi: 10.4049/jimmunol.168.5.2096 – ident: 2022123119205825700_R24 doi: 10.1073/pnas.0508666102 – ident: 2022123119205825700_R15 doi: 10.4049/jimmunol.156.1.5 – ident: 2022123119205825700_R32 doi: 10.1196/annals.1394.023 – ident: 2022123119205825700_R21 doi: 10.2741/2390 – ident: 2022123119205825700_R18 doi: 10.4049/jimmunol.177.1.566 – ident: 2022123119205825700_R17 doi: 10.4049/jimmunol.176.12.7768 – ident: 2022123119205825700_R10 doi: 10.1016/j.jneuroim.2004.06.007 – ident: 2022123119205825700_R27 doi: 10.1172/JCI25308 – ident: 2022123119205825700_R28 doi: 10.1016/j.immuni.2006.06.002 – ident: 2022123119205825700_R30 doi: 10.1086/444430 – ident: 2022123119205825700_R31 doi: 10.1182/blood-2004-08-3228 – ident: 2022123119205825700_R11 doi: 10.1038/ni1415 – ident: 2022123119205825700_R2 doi: 10.1172/JCI200319190 – ident: 2022123119205825700_R26 doi: 10.1038/nature01355 – ident: 2022123119205825700_R6 doi: 10.1136/gut.2004.048298 – ident: 2022123119205825700_R20 doi: 10.1038/nm1715 – ident: 2022123119205825700_R22 doi: 10.1038/ni1496 – ident: 2022123119205825700_R29 doi: 10.1016/S1074-7613(03)00113-4 |
| SSID | ssj0006024 |
| Score | 2.367826 |
| Snippet | Osteopontin (Opn) is a broadly expressed pleiotropic cytokine, and has been shown to play an important role in various autoimmune diseases, including multiple... Osteopontin (Opn) is a broadly expressed pleiotropic cytokine and has been shown to play an important role in various autoimmune diseases including multiple... |
| SourceID | pubmedcentral proquest pubmed crossref highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 7480 |
| SubjectTerms | Animals Antibodies - pharmacology Cell Differentiation - immunology Cells, Cultured Dendritic Cells - immunology Encephalomyelitis, Autoimmune, Experimental - genetics Encephalomyelitis, Autoimmune, Experimental - immunology Gene Expression Regulation - drug effects Gene Expression Regulation - immunology Humans Hyaluronan Receptors - genetics Hyaluronan Receptors - immunology Integrin alphaV - genetics Integrin alphaV - immunology Integrin beta3 - genetics Integrin beta3 - immunology Interferon-gamma - genetics Interferon-gamma - immunology Interleukin-10 - genetics Interleukin-10 - immunology Interleukin-17 - genetics Interleukin-17 - immunology Mice Mice, Knockout Multiple Sclerosis - genetics Multiple Sclerosis - immunology Osteopontin - antagonists & inhibitors Osteopontin - genetics Osteopontin - immunology Th1 Cells - immunology |
| Title | Increased Osteopontin Expression in Dendritic Cells Amplifies IL-17 Production by CD4+ T Cells in Experimental Autoimmune Encephalomyelitis and in Multiple Sclerosis |
| URI | http://www.jimmunol.org/cgi/content/abstract/181/11/7480 https://www.ncbi.nlm.nih.gov/pubmed/19017937 https://www.proquest.com/docview/69808596 https://pubmed.ncbi.nlm.nih.gov/PMC2653058 |
| Volume | 181 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIhAXBOUVnotET5ZTvx9HSIEWWsQhlXqzdu01sZrYEXYUhf_DT-L_MONdv0okoJcodnbXdubbnZn1zDeEvLGE7dqGEescU9wd13X1gIHj6rgOE65IPM4xG_nsi3d87ny6cC9Go1-9qKV1xSfxj515JdeRKpwDuWKW7H9Ith0UTsB3kC98goTh859kDJMbY8rBZsRUjWJVYNkHJO2Xwa25DHXNk7qcgYZ79KXGMIQ8Bf9YOznVTR8DtBLJIIuW6PTIObDeaTPVOLtSAoCtqyLDjBKh4YqwmrNFsdwKDKErFY9TF6JYwt2CDs7KvgHcpaJJtgocTNJAHdQv24ze1gSAYP2NZVu5R_sR3PsuiDGrKibjCy5ZflnOO-0iMpXDIyOCtdPJYGcj6EWJdJkGpi_LdUyEWqBdcHc9wxuu4GYfqmZvQfYdWShKKXc4DHYpDgccJVQc6qknMCIok0nTu4el1bIGE9pRSC3YqdE2uPHr2dTyYAK4wQ1y0wLvBQtrHJ18bg0Ez7CchsQeH09mdOItHO66gZrXVl5taDw1hNa7nKOrMb49o2l2j9xVgqZvJXTvk5HI98ktWf90u09un6nIjgfkZ4tl2sMy7bBM4ajFMq3hSVss0xrLtMMy5VsKWNboTDWVY7VIph2S6R9IpoBk7NAgmbZIfkjOP7yfTY91VUJEjx3fqvTUMlMhXDMBzyTxHJYmPIlTHsdJEHDLC1lQv3lPWWynLBB-TXAIeoxzE213y35E9vIiF08IFcznRhiEZoKUfKETCHx_kNqe6ychN_mY2I1soljx62OZl0UEfjYKN2qEG4FwwfOOULhjore9VpJf5i_tXzdij8olWyxAyma02WwGbV41eIhAWeDfzHJRrMvICwMkNPTG5LFER3dNhbAx8Qe4aRsgDf3wlzyb13T0CuxPr93zGbnTTf_nZK_6vhYvwNSv-Mt64vwGO1MHnQ |
| linkProvider | Flying Publisher |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Increased+osteopontin+expression+in+dendritic+cells+amplifies+IL-17+production+by+CD4%2B+T+cells+in+experimental+autoimmune+encephalomyelitis+and+in+multiple+sclerosis&rft.jtitle=The+Journal+of+immunology+%281950%29&rft.au=Murugaiyan%2C+Gopal&rft.au=Mittal%2C+Akanksha&rft.au=Weiner%2C+Howard+L.&rft.date=2008-12-01&rft.issn=0022-1767&rft.eissn=1550-6606&rft.volume=181&rft.issue=11&rft.spage=7480&rft.epage=7488&rft_id=info:doi/10.4049%2Fjimmunol.181.11.7480&rft_id=info%3Apmid%2F19017937&rft.externalDocID=PMC2653058 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1767&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1767&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1767&client=summon |